Oral 2-chlorodeoxyadenosine in psoriatic arthritis. A preliminary report.
OBJECTIVE
To determine if weekly oral 2-chlorodeoxyadenosine (2-CdA) can induce selective lymphocytopenia, and reduce inflammation, in patients with refractory psoriatic arthritis.


METHODS
Seven patients with psoriatic arthritis were treated with oral 2-CdA at weekly dosages of 0.3 mg/kg to 0.45 mg/kg for 12 weeks, followed by monthly maintenance therapy. The patients were evaluated after 6 months.


RESULTS
The drug treatment produced selective lymphocytopenia, and reduced lymphocyte infiltration into involved skin. One patient did not complete 12 weeks of therapy because of perceived lack of efficacy. Four of the 6 remaining patients had improved joint disease, and 5 of 6 had improved psoriasis.


CONCLUSIONS
Weekly oral 2-CdA appears to be a well-tolerated regimen for the inducement of peripheral lymphocytopenia in patients with psoriatic arthritis. Larger-scale, controlled trials may be warranted.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D015535:Arthritis, Psoriatic / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D001706:Biopsy; D016516:CD4-CD8 Ratio; D017338:Cladribine / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D018655:Lymphocyte Count / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance
D017338:Cladribine